Annabel Samimy

Joseph Stringer

Yatin Suneja

Kristen Kluska

Matthew Caufield

Chase Knickerbocker

Chengxiang Liu

Kyuwon Choi

Paul Choi

Jyhhaw Liu

Umer Raffat

- Phathom Pharmaceuticals is reallocating the majority of its salesforce time to **gastroenterologists** (GIs) starting in **July**, shifting from a previous strategy where **over 60% of sales calls** were directed at primary care physicians.  **[1783183_tx_379120_0]** **[1783183_tx_379120_1]** **[1783183_tx_379120_5]**  This change is driven by GIs yielding **four times the productivity** in terms of scripts per call for VOQUEZNA.  **[1783183_tx_379120_1]** 
- The company's focus is on the **30-40% of GERD patients (tens of millions)** who continue to experience pain despite current PPI therapy, as VOQUEZNA offers a superior mechanism to elevate stomach pH.  **[1783183_tx_379120_0]** **[1783183_tx_379120_4]** **[1783183_tx_379120_8]** 
- A recent citizen petition clarified VOQUEZNA's regulatory exclusivity period, extending it to **May 2032**, with generic entry not anticipated until **well into 2033**.  **[1783183_tx_379120_7]** 
- This revamped strategy, coupled with expense reductions, is projected to lead to **EBIT positive operations by sometime next year** and **positive cash flow shortly thereafter**, providing a multi-year runway for value creation.  **[1783183_tx_379120_7]**

Phathom Pharmaceuticals outlines strategic shift for VOQUEZNA and extended exclusivity

Phathom Pharmaceuticals (PHAT)